Mumbai, September 5 (Kiran News) — Shares of Glenmark Pharmaceuticals rose on Friday after the company announced it has initiated a multi-country Phase 3 clinical trial for Envafolimab, a novel subcutaneous PD-L1 inhibitor, in patients with resectable Stage III Non-Small Cell Lung Cancer (NSCLC).
At 11:00 am, the stock was trading at ₹2,045.75, up 2.77% from its previous close of ₹1,990.60 on the BSE. The scrip opened at ₹1,990.60 and touched an intraday high of ₹2,055.15 and a low of ₹1,990.60. A total of 15,447 shares were traded on the counter.
The BSE ‘A’ group stock, with a face value of ₹1, has a 52-week high of ₹2,286.15 (July 11, 2025) and a 52-week low of ₹1,274.70 (Feb 28, 2025). Its current market capitalisation stands at ₹57,879.39 crore. Promoters hold 46.65%, while institutional and non-institutional investors own 38.30% and 15.06% respectively.
Glenmark said it has received approval from the Drugs Controller General of India (DCGI) to begin patient enrolment and dosing in India. In parallel, the company has submitted a Clinical Trial Application (CTA) in Russia and is preparing to open additional trial sites in Brazil and Mexico, extending the study’s global footprint.
The randomized, multi-center Phase 3 trial will evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of Envafolimab in patients with resectable Stage IIIA and IIIB (N2) NSCLC. A parallel Phase 3 study of Envafolimab, sponsored by 3D Medicines Inc., has been underway in China since December 2023.
Lung cancer is the leading cause of cancer-related deaths worldwide, with NSCLC accounting for 80–85% of cases. Around 20–30% are diagnosed at Stage III, where survival outcomes remain poor despite surgical interventions, highlighting the urgent need for novel immunotherapy solutions like Envafolimab.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company, operating across Generics, Specialty, and OTC businesses, with a presence in over 50 countries.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.
